Credit: Getty Images. The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study. A decision was made to discontinue all ...
High–Temporal/High–Spatial Resolution Breast Magnetic Resonance Imaging Improves Diagnostic Accuracy Compared With Standard Breast Magnetic Resonance Imaging in ...
On March 14, 2022, Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) announced that the Phase 3 PIVOT IO-001 trial of bempegaldesleukin (NKTR-214) in combination with Opdivo ...
Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the ...
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth ...
Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company based in San Francisco, is focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic ...
SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with ...
SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results